A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT06559176 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Granulomatous Disease
Granulomatous Disease, Chronic

Interventions

BIOLOGICAL: PM359

Sponsor

Prime Medicine, Inc.